Forte Biosciences (FBRX) Price & Analysis

Compare

320 Followers

FBRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.11 - $28.68

Previous CloseN/A

Volume20.10K

Average Volume (3M)54.39K

Market Cap

$140.68M

Enterprise Value$45.71M

Total Cash (Recent Filing)$106.14M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.75

Next Earnings

Nov 17, 2025

EPS Estimate

-0.96

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.96

Shares Outstanding12,432,854

10 Day Avg. Volume46,778

30 Day Avg. Volume54,388

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.32

Enterprise Value/Revenue1.20K

Enterprise Value/Gross Profit-2.41K

Enterprise Value/Ebitda-1.05

Forecast

1Y Price Target

$52.33

Price Target Upside362.28% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsForte Biosciences has dosed the first patients in their Phase 2 trial for their lead asset FB102 in celiac disease, with data expected to be positive given strong results from the previous Phase 1b trial.

Financial PerformanceThe company recently closed a $70 million net public offering, bringing their cash reserves to $106 million, which supports ongoing and future trials.

Research And DevelopmentAnother Phase 1b trial in alopecia areata has been initiated, with data expected in the future, indicating ongoing research and development progress.

Bears Say

Cash ReservesCash at $46M.

Operational ExpensesForte Biosciences reported Q1 OpEx of ($16M), above our ($10M) estimate.

Forte Biosciences News

Forte Biosciences initiated with a Buy at Guggenheim on FB102 potential

As previously reported, Guggenheim initiated coverage of Forte Biosciences (FBRX) with a Buy rating and $75 price target...

9d ago

FBRX

Forte Biosciences initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Forte Biosciences (FBRX) with a Buy rating and $75 price target Published first on...

9d ago

FBRX

Forte Biosciences reports Q2 EPS (96c), consensus ($1.11)

“I am deeply appreciative of the Forte team’s incredible accomplishments in initiating 3 clinical trials for FB102 with...

13d ago

FBRX

Forte Biosciences Reports Q2 2025 Financial Results

Forte Biosciences Inc. ( ($FBRX) ) has released its Q2 earnings. Here is a breakdown of the information...

8d ago

FBRX

Forte Biosciences Announces Q2 2025 Results and Trials

The latest update is out from Forte Biosciences ( ($FBRX) ). On August 14, 2025, Forte Biosciences announced...

13d ago

FBRX

Sixteen new option listings on July 23rd

New option listings for July 23rd include ABVC Biopharma Inc (ABVC), Astex Pharmaceuticals Inc (ASTX), Bitmine Immersion Technologies...

1M ago

RAL

SMU

Forte Biosciences Announces Public Offering of Shares

Forte Biosciences ( ($FBRX) ) just unveiled an update. On June 24, 2025, Forte Biosciences announced a public...

2M ago

FBRX

Forte Biosciences announces common stock offering, no amount given

Forte Biosciences (FBRX) announced that it has commenced an underwritten public offering of shares of its common stock...

2M ago

FBRX

Forte Biosciences Stock (FBRX) Surges 25% on Positive Celiac Disease Trial Data

Forte Biosciences stock rocketed higher on Monday after it posted positive results from a Phase 1b trial. ...

2M ago

FBRX

Forte Biosciences Announces Positive Phase 1b Trial Results

Forte Biosciences ( ($FBRX) ) just unveiled an announcement. On June 23, 2025, Forte Biosciences announced positive results...

2M ago

FBRX

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

It’s time to dive into the biggest stock market stories investors need to know about on Monday. ...

2M ago

ACN

AMD

Forte Biosciences announces data from trial in celiac disease for FB102

Forte Biosciences (FBRX) announced data from a Phase 1b trial in celiac disease for lead program FB102. The...

2M ago

FBRX

Forte Biosciences initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Forte Biosciences (FBRX) with a Buy rating and $28 price target entered clinical...

3M ago

FBRX

Forte Biosciences Elects New Directors at Annual Meeting

Forte Biosciences ( ($FBRX) ) has provided an update. On May 29, 2025, Forte Biosciences held its annual...

3M ago

FBRX

FBRX FAQ

What was Forte Biosciences Inc.’s price range in the past 12 months?

Forte Biosciences Inc. lowest stock price was $4.11 and its highest was $28.68 in the past 12 months.

What is Forte Biosciences Inc.’s market cap?

Forte Biosciences Inc.’s market cap is $140.68M.

When is Forte Biosciences Inc.’s upcoming earnings report date?

Forte Biosciences Inc.’s upcoming earnings report date is Nov 17, 2025 which is in 82 days.

How were Forte Biosciences Inc.’s earnings last quarter?

Forte Biosciences Inc. released its earnings results on Aug 14, 2025. The company reported -$0.96 earnings per share for the quarter, beating the consensus estimate of -$1.108 by $0.148.

Is Forte Biosciences Inc. overvalued?

According to Wall Street analysts Forte Biosciences Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Forte Biosciences Inc. pay dividends?

Forte Biosciences Inc. does not currently pay dividends.

What is Forte Biosciences Inc.’s EPS estimate?

Forte Biosciences Inc.’s EPS estimate is -0.96.

How many shares outstanding does Forte Biosciences Inc. have?

Forte Biosciences Inc. has 12,432,854 shares outstanding.

What happened to Forte Biosciences Inc.’s price movement after its last earnings report?

Forte Biosciences Inc. reported an EPS of -$0.96 in its last earnings report, beating expectations of -$1.108. Following the earnings report the stock price went up 6.932%.

Which hedge fund is a major shareholder of Forte Biosciences Inc.?

Currently, no hedge funds are holding shares in FBRX

Forte Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-73.46%

Trailing 12-Months

Asset Growth

313.31%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Forte Biosciences Inc.

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Forte Biosciences (FBRX) Earnings & Revenues

Historic Earnings Reports

FBRX Stock 12 Month Forecast

Average Price Target

$52.33

▲(362.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","76":"$76","21.25":"$21.3","39.5":"$39.5","57.75":"$57.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,21.25,39.5,57.75,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.61,14.64,19.67,24.7,29.73,34.760000000000005,39.79,44.82,49.85,54.88,59.910000000000004,64.94,69.97,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.61,12.896153846153846,16.182307692307692,19.46846153846154,22.754615384615384,26.04076923076923,29.326923076923077,32.613076923076925,35.89923076923077,39.18538461538461,42.47153846153846,45.75769230769231,49.043846153846154,{"y":52.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.61,11.024615384615384,12.439230769230768,13.853846153846153,15.268461538461537,16.68307692307692,18.097692307692306,19.512307692307694,20.926923076923075,22.341538461538462,23.756153846153843,25.17076923076923,26.585384615384616,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.48,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.69,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.78,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.84,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.71,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.89,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.83,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >